Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40


Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.

Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, Scott VL, Reuschel EL, Zaidi FI, Duperret EK, Wise MC, Kraynyak KA, Ugen KE, Sardesai NY, Joseph Kim J, Weiner DB.

Cancer Immunol Immunother. 2017 Aug 17. doi: 10.1007/s00262-017-2042-7. [Epub ahead of print]


Protocols for Developing Novel Chikungunya Virus DNA Vaccines.

Chung C, Ugen KE, Sardesai NY, Weiner DB, Muthumani K.

Methods Mol Biol. 2016;1426:311-32. doi: 10.1007/978-1-4939-3618-2_28.


Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus.

Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, Sarangan G, Srikanth P, Khan AS, Vijayachari P, Sardesai NY, Kim JJ, Ugen KE, Weiner DB.

J Infect Dis. 2016 Aug 1;214(3):369-78. doi: 10.1093/infdis/jiw111. Epub 2016 Mar 21.


A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.

Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga AM, Soule G, Morrow M, Kraynyak KA, Khan AS, Scott DP, Feldmann F, LaCasse R, Meade-White K, Okumura A, Ugen KE, Sardesai NY, Kim JJ, Kobinger G, Feldmann H, Weiner DB.

Sci Transl Med. 2015 Aug 19;7(301):301ra132. doi: 10.1126/scitranslmed.aac7462.


DNA vaccines 2014 meeting: Highlights and overview.

Ugen KE, Weiner DB.

Hum Vaccin Immunother. 2015;11(8):1887-8. doi: 10.1080/21645515.2015.1066947. No abstract available.


Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations.

Kudrna JJ, Ugen KE.

Hum Vaccin Immunother. 2015;11(8):1921-6. doi: 10.1080/21645515.2015.1065364. Review.


Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease.

Ugen KE, Lin X, Bai G, Liang Z, Cai J, Li K, Song S, Cao C, Sanchez-Ramos J.

Hum Vaccin Immunother. 2015;11(4):922-30. doi: 10.1080/21645515.2015.1012033.


Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.

Shahaduzzaman M, Nash K, Hudson C, Sharif M, Grimmig B, Lin X, Bai G, Liu H, Ugen KE, Cao C, Bickford PC.

PLoS One. 2015 Feb 6;10(2):e0116841. doi: 10.1371/journal.pone.0116841. eCollection 2015.


Review of gene vaccines book.

Ugen KE.

Hum Vaccin Immunother. 2014;10(7):1926. doi: 10.4161/hv.28856. No abstract available.


Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity.

Shedlock DJ, Tingey C, Mahadevan L, Hutnick N, Reuschel EL, Kudchodkar S, Flingai S, Yan J, Kim JJ, Ugen KE, Weiner DB, Muthumani K.

Vaccines (Basel). 2014 Mar 25;2(2):196-215. doi: 10.3390/vaccines2020196.


Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.

Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB.

Hum Vaccin Immunother. 2013 Oct;9(10):2253-62. doi: 10.4161/hv.26498. Epub 2013 Sep 17.


Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine.

Bao H, Ramanathan AA, Kawalakar O, Sundaram SG, Tingey C, Bian CB, Muruganandam N, Vijayachari P, Sardesai NY, Weiner DB, Ugen KE, Muthumani K.

Viral Immunol. 2013 Feb;26(1):75-83. doi: 10.1089/vim.2012.0061.


Electrogenetherapy of B16.F10 murine melanoma tumors with an interleukin-28 expressing DNA plasmid.

Shah K, Connolly RJ, Chapman T, Jaroszeski MJ, Ugen KE.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1722-8. doi: 10.4161/hv.22560. Epub 2012 Nov 1.


Non-contact helium-based plasma for delivery of DNA vaccines. Enhancement of humoral and cellular immune responses.

Connolly RJ, Chapman T, Hoff AM, Kutzler MA, Jaroszeski MJ, Ugen KE.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1729-33. doi: 10.4161/hv.21624. Epub 2012 Aug 16.


DNA vaccines 2010: a gumbo of accomplishment and excitement in New Orleans.

Ugen KE, Sardesai N, Weiner DB.

Vaccine. 2011 Sep 9;29(39):6721-2. doi: 10.1016/j.vaccine.2011.07.026. Epub 2011 Jul 16. No abstract available.


Enhancement of antigen specific humoral immune responses after delivery of a DNA plasmid based vaccine through a contact-independent helium plasma.

Connolly RJ, Rey JI, Lambert VM, Wegerif G, Jaroszeski MJ, Ugen KE.

Vaccine. 2011 Sep 9;29(39):6781-4. doi: 10.1016/j.vaccine.2010.12.054. Epub 2010 Dec 31.


Anti-cancer activity of the HIV accessory molecule viral protein R (Vpr): Delivery as a DNA expression plasmid or biologically active peptides.

Muthumani K, Lambert VM, Kawalekar O, Heller R, Kim JJ, Weiner DB, Ugen KE.

Vaccine. 2010 Feb 23;28(8):2005-10. doi: 10.1016/j.vaccine.2009.10.060.


Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant.

Li QY, Gordon MN, Chackerian B, Alamed J, Ugen KE, Morgan D.

J Neuroimmune Pharmacol. 2010 Mar;5(1):133-42. doi: 10.1007/s11481-009-9183-1.


Analysis of the potential for HIV-1 Vpr as an anti-cancer agent.

Muthumani K, Lambert VM, Sardesai NY, Kim JJ, Heller R, Weiner DB, Ugen KE.

Curr HIV Res. 2009 Mar;7(2):144-52. Review.


Supplemental Content

Loading ...
Support Center